The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 219-223

  McColl, Damian J ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Antiretrovirals; HIV; Resistance; Tenofovir

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PRODRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ABSORPTION; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ADENINE; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037326980     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg109     Document Type: Article

References (33)

1. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338, 853-60.
2. Loveday, C. (2001). International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 26, Suppl. 1, S10-24.
3. Roberts, J. D., Bebenek, K. & Kunkel, T. A. (1988). The accuracy of reverse transcriptase from HIV-1. Science 242, 1171-3.
4. Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J. & De Clercq, E. (1997). HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry and Chemotherapy 8, 1-23.
5. Arimilli, M., Kim, C. & Bischofberger, N. (1997). Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)propyl]adenine (PMPA). Antiviral Chemistry and Chemotherapy 8, 557-64.
6. Naesens, L., Bischofberger, N., Augustijns, P., Annaert, P., Van den Mooter, G., Arimilli, M. N. et al. (1998). Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl) adenine in mice. Antimicrobial Agents and Chemotherapy 42, 1568-73.
7. Balzarini, J., Holý, A., Jindrich, J., Naesens, L., Snoeck, R., Schols, D. et al. (1993). Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrobial Agents and Chemotherapy 37, 332-8.
8. Robbins, B. L., Srinivas, R. V., Kim, C., Bischofberger, N. & Fridland, A. (1998). Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrobial Agents and Chemotherapy 42, 612-7.
9. Robbins, B. L., Greenhaw, J. J., Connelly, M. C. & Fridland, A. (1995). Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrobial Agents and Chemotherapy 39, 2304-8.
10. Miller, V. & Larder, B. A. (2001). Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Therapy 6, Suppl. 3, 25-44.
11. Sarafianos, S. G., Das, K. D., Clark, A. D., Ding, J., Boyer, P. L., Hughes, S. H. et al. (1999). Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proceedings of the National Academy of Sciences, USA 96, 10027-32.
12. Meyer, P. R., Matsuura, S. E., So, A. G. & Scott, W. A. (1998). Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proceedings of the National Academy of Sciences, USA 95, 13471-7.
13. Meyer, P. R., Matsuura, S. E., Schinazi, R. F., So, A. G. & Scott, W. A. (2000). Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrobial Agents and Chemotherapy 44, 3465-72.
14. Skowron, G., Whitcomb, J., Wesley, M., Petropoulos, C., Hellmann, N., Holodniy, M. et al. (1999). Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V (Abstract 81). Antiviral Therapy 4, Suppl. 1, 55-6.
15. Tisdale, M., Alnadaf, T. & Cousens, D. (1997). Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents and Chemotherapy 41, 1094-8.
16. Opravil, M., Yerly, S., Staszewski, S., Stone, C., Ait-Khaled, M. & Perrin, L. (2000). Prior treatment with mono or dual NRTIs before HAART as predictor of virological failure in simplified abacavir-based triple NRTI regimens: results from the Simplified Maintenance Trial (SMT) and CNA30017 (Abstract 120). Antiviral Therapy 5, Suppl. 3, 95-6.
17. Lanier, E. R., Hellmann, N., Scott, J., Ait-Khaled, M., Melby, T., Carsanaro, J. et al. (2001). Determination of a clinically relevant phenotypic resistance 'cutoff' for abacavir using the PhenoSense assay. In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 2001. Abstract 254, p. 117. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W.-Y., Kojima, E., Alcaide, M. L. et al. (1995). Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA 92, 2398-402.
19. Larder, B. A., Bloor, S., Kemp, S. D., Hertogs, K., Desmet, R. L., Miller, V. et al. (1999). A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents and Chemotherapy 43, 1961-7.
20. Wainberg, M. A., Miller, M. D., Quan, Y., Salomon, H., Mulato, A. S., Lamy, P. D. et al. (1999). In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4, 87-94.
21. Srinivas, R. V. & Fridland, A. (1998). Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyl-oxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrobial Agents and Chemotherapy 42, 1484-7.
22. Miller, M. D., Anton, K. E., Mulato, A. S., Lamy, P. D. & Cherrington, J. M. (1999). Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Journal of Infectious Diseases 179, 92-100.
23. Miller, M. D., Margot, N. A., Hertogs, K., Larder, B. & Miller, V. (2000). Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 2115, p. 350. American Society for Microbiology, Washington, DC, USA.
24. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M. A., Goldberg, E. et al. (1994). Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 38, 275-81.
25. De Antoni, A., Foli, A., Lisziewicz, J. & Lori, F. (1997). Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. Journal of Infectious Diseases 176, 899-903.
26. Bloor, S., Kemp, S. D., Hertogs, K., Alcorn, T. & Larder, B. A. (2000). Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12000 samples from the USA in 1999. Antiviral Therapy 5, Suppl. 3, 132.
27. Margot, N. A., Isaacson, E., McGowan, I., Cheng, A. K., Schooley, R. T. & Miller, M. D. (2002). Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16, 1227-35.
28. Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D. et al. (2002). Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16, 1257-63.
29. Squires, K., Pierone, G., Berger, D., Steinhart, C., Bellos, N., Becker, S. L. et al. (2002). A 48-week final analysis from a phase III randomized, double blind, placebo controlled study in antiretroviral experienced patients (study 907). In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 413-W, p. 209. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
30. Miller, M. D., Margot, N. A. & Lu, B. (2002). Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 43, p. 68. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
31. Margot, N. A., Johnson, A., Coakley, D. F., Cheng, A. & Miller, M. D. (2002). Final 48 week genotypic and phenotypic analyses of study 907: tenofovir DF (TDF) added to stable background regimens. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 414-W, p. 209. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
32. Selmi, B., Boretto, J., Sarfati, S. R., Guerreiro, C. & Canard, B. (2001). Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. Journal of Biological Chemistry 276, 48466-72.
33. White K. L., Margot, N. A., Wrin, T., Petropoulos, C. J., Miller, M. D. & Naeger, L. K. (2002). Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrobial Agents and Chemotherapy 46, 3437-46.